Navigation Links
GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology
Date:10/24/2008

GenOdyssee Has Received Notice of Allowance of European Patent Application

Covering Its Core Natural Evolution Technology Invented in 2002, and Received Broad Product Applications Protection Rights to All Cytokine

Families

PARIS, October 24 /PRNewswire/ -- GenOdyssee (GO), a biotechnology company dedicated to the discovery and development of improved 'next generation' human protein therapeutics, announced today that it has received notice of allowance from the European Patent Office of its Patent Application no.3 785 733.1 (PCT/EP03/13965) covering its core founding drug discovery technology process entitled "Method For Providing Natural Therapeutic Agents With High Therapeutic Index" for applications to all therapeutic cytokine families.

The company pioneered the vision that natural evolution has created in the general population superior genetic variants of key human protein therapeutic drugs as compared to the first wave of reference protein therapeutic variants isolated and developed during the first biotech boom in the 80s, which currently constitute standard of care.

"We have always believed that our technology has wide potential in the industry for discovery of second generation products. Our IFN and EPO products have been granted IP in all major countries in which we filed a product patent application, including the EU and the USA. Our IP portfolio now extends to 53 patents and patent applications in more than 19 countries. Importantly, the European patent office has now granted our technology broad product protection rights across all cytokine families. The granting of such broad IP product rights is relatively unusual and has been achieved in this case because GenOdyssee successfully demonstrated successful application of its technology across multiple products in various cytokine families," said Dr. David Brown, senior executive advisor for science & bus dev to GenOdyssee.

"This
'/>"/>

SOURCE GenOdyssee SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
2. Alfacell Receives Going Concern Audit Opinion
3. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
4. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
5. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
6. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
7. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
8. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
9. Althea Technologies Receives Fast Growth Honors: Deloitte Technology Fast 50 and San Diego Business Journal Fast 100 Awards for the Fifth Consecutive Year
10. POET Receives Additional $76 Million in Federal Funding For Commercialization of Cellulosic Ethanol
11. Imaging Diagnostic Systems Receives its First Order for its CT Laser Mammography System for Israel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) has ... of bio-succinic acid used to produce a new ... that Bayer MaterialScience has begun commercializing.    ... eco, a series of bio-based waterborne polyurethane dispersions ... 65%.  IMPRANIL ® eco has been developed ...
(Date:4/24/2015)... April 24 , 2015 PAREXEL International ... services provider, today announced that Partnerships in Clinical Trials ... Management, the 2015 Clinical Innovator of the Year.  The ... team for the Company,s Perceptive MyTrials ® Data-Driven ... Thursday night during the 2015 Partnership Awards in ...
(Date:4/23/2015)... Dora, Florida (PRWEB) April 23, 2015 ... that it intends to conduct a groundbreaking pilot ... begin to be reversed in as little as ... the science of metabolic and nutritional medicine—will aggressively ... that cripple and destroy our aging brain. These ...
(Date:4/23/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... quarter 2015 results before the Nasdaq market opens on ... conference call and webcast to discuss its financial results ... 2015 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific ... call by dialing 866-952-1906 (US) or 785-424-1825 (International) using ...
Breaking Biology Technology:Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 3Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2
... NeoStem, Inc.,(NYSE Alternext US: NBS), which is pioneering the pre-disease ... medical need,today announced that it has completed an above market ... $1.25 per unit with each unit,consisting of one share of ... stock at $1.75 per share. , ...
... SAN FRANCISCO, Calif., Dec. 3 Portola,Pharmaceuticals, a ... in cardiovascular disease, inflammatory disease,and cancer, today announced ... novel,compounds that inhibit spleen tyrosine kinase (Syk) and ... presented at the annual meeting of the,American Society ...
... , , QUEBEC CITY, ... AEZS ; TSX: AEZ), a global biopharmaceutical company ... has completed the transaction under the previously announced purchase ... ("CHRP") relating to AEterna Zentaris, rights to royalties on ...
Cached Biology Technology:NeoStem Completes $500,000 Private Placement With Strategic Investor 2NeoStem Completes $500,000 Private Placement With Strategic Investor 3Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 2Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 3AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 2AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 3
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... enhanced the abilities of the molecules they are creating ... molecular complexes enter cancer cells and, when signaled, deliver ... new supermolecules have more units that will absorb light ... frequencies that can be included and excluded as signals ...
... DNA isn't just for storing genetic codes any more. ... into larger structures -- scientists have been using it ... even working mechanical devices. , Now Cornell University researchers ... could be used for drug delivery and as containers ...
... have become invaluable decision-making tools for public health ... epidemic of 2001, models can be useful in ... of an infection and they can allow the ... models make implicit assumptions that may systematically bias ...
Cached Biology News:Virginia Tech group adds tools to DNA-targeted anti-cancer drugs 2Virginia Tech group adds tools to DNA-targeted anti-cancer drugs 3Self-assembled DNA buckyballs for drug delivery 2Self-assembled DNA buckyballs for drug delivery 3Understanding biases in epidemic models important when making public health predictions 2
...
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
Homo sapiens jumping translocation breakpoint...
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
Biology Products: